Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding: 2019-2025

Historic Shares Outstanding for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $74.2 million.

  • C4 Therapeutics' Shares Outstanding rose 5.12% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 5.12%. This contributed to the annual value of $70.6 million for FY2024, which is 16.80% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Shares Outstanding is $74.2 million, which was up 4.46% from $71.0 million recorded in Q2 2025.
  • C4 Therapeutics' Shares Outstanding's 5-year high stood at $74.2 million during Q3 2025, with a 5-year trough of $43.1 million in Q1 2021.
  • Over the past 3 years, C4 Therapeutics' median Shares Outstanding value was $68.8 million (recorded in 2024), while the average stood at $63.9 million.
  • Data for C4 Therapeutics' Shares Outstanding shows a peak YoY spiked of 3,146.25% (in 2021) over the last 5 years.
  • Over the past 5 years, C4 Therapeutics' Shares Outstanding (Quarterly) stood at $48.7 million in 2021, then grew by 0.57% to $49.0 million in 2022, then rose by 23.49% to $60.5 million in 2023, then rose by 16.80% to $70.6 million in 2024, then increased by 5.12% to $74.2 million in 2025.
  • Its last three reported values are $74.2 million in Q3 2025, $71.0 million for Q2 2025, and $71.0 million during Q1 2025.